Production (Stage)
Evogene Ltd.
EVGN
$1.38
-$0.14-9.21%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 9.45M | 9.19M | 5.64M | 5.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 9.45M | 9.19M | 5.64M | 5.72M |
| Cost of Revenue | -- | 1.76M | 1.68M | 1.69M | 1.66M |
| Gross Profit | -- | 7.69M | 7.51M | 3.95M | 4.06M |
| SG&A Expenses | -- | 9.74M | 10.01M | 9.68M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -3.50M |
| Total Operating Expenses | -- | 30.92M | 32.47M | 32.15M | 28.38M |
| Operating Income | -- | -21.48M | -23.28M | -26.51M | -22.66M |
| Income Before Tax | -- | -21.03M | -22.81M | -25.99M | -22.42M |
| Income Tax Expenses | -- | -8.00K | 12.00K | -33.00K | 16.00K |
| Earnings from Continuing Operations | -- | -21.03 | -22.82 | -25.95 | -22.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 1.16M | 1.35M | 2.08M | 2.16M |
| Net Income | -- | -19.87M | -21.47M | -23.88M | -20.28M |
| EBIT | -- | -21.48M | -23.28M | -26.51M | -22.66M |
| EBITDA | -- | -18.87M | -20.64M | -23.90M | -20.07M |
| EPS Basic | -- | -3.94 | -4.57 | -5.32 | -4.74 |
| Normalized Basic EPS | -- | -1.88 | -2.24 | -2.24 | -1.75 |
| EPS Diluted | -- | -3.94 | -4.57 | -5.32 | -4.74 |
| Normalized Diluted EPS | -- | -1.88 | -2.24 | -2.24 | -1.75 |
| Average Basic Shares Outstanding | -- | 20.12M | 19.20M | 18.26M | 17.33M |
| Average Diluted Shares Outstanding | -- | 20.12M | 19.20M | 18.26M | 17.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |